Information for Administration Sites
The increased incidence of the Delta variant of SARS-CoV-2 has caused a substantial surge in the utilization of monoclonal antibody (mAb) drugs, particularly in areas of the country with low vaccination rates. HHS is committed to helping ensure consistent availability of these critical drugs for current and future patients in all geographic areas of the country. As such, we have updated the distribution process for
REGEN-COV and
bamlanivimab/etesevimab.
On Monday, September 13, HHS transitioned from a direct ordering process to a state/territory-coordinated distribution system similar to that used for the distribution of mAbs from November 2020 – February 2021.
State and territorial health departments know best where product is needed in their areas. Transitioning to a state/territory-coordinated distribution system gives health departments maximum flexibility to get these critical drugs where they are needed most.
HHS will determine the weekly amount of mAb products each state and territory receives based on COVID-19 case burden and mAb utilization. State and territorial health departments will subsequently identify which sites in their respective jurisdictions receive product as well as the amount each site receives.
As of Monday, September 13, 2021:
- Administration sites no longer order directly from AmerisourceBergen.
- Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted to the federal government.
- State/Territorial Health Departments will determine where product goes in their jurisdictions.
|
Please contact us at COVID19Therapeutics@HHS.gov if you need information regarding how to connect with your state/territorial health department official.
Note: The COVID-19 monoclonal antibody Sotrovimab is not distributed by the U.S. Government. Please contact the manufacturer for information on purchasing this product.
